CTOs on the Move

Metabiota

www.metabiota.com

 
Metabiota is the pioneer in comprehensive risk analytics that improve the world`s resilience to epidemics. Built on a strong foundation of epidemiology and international field science, including a worldwide network of on-the-ground experts, Metabiota delivers actionable, data-driven insights that help countries, governments and corporations manage and mitigate infectious diseases. With a strategic global presence and sustained partnerships, Metabiota`s agile approach is helping the world track and transfer the risk associated with epidemic threats.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.metabiota.com
  • 425 California 2nd Floor
    San Francisco, CA USA 94104
  • Phone: 415.398.4712
  • Fax: 415.398.4716

Executives

Name Title Contact Details

Funding

Metabiota raised $30M on 05/20/2015

Similar Companies

Cytovance

Cytovance® Biologics is a biopharmaceutical contract manufacturing company specializing in clinical and commercial manufacturing production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities.

Stem Cell Therapeutics

Stem Cell Therapeutics Corp. is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aeris Therapeutics Inc

Aeris Therapeutics Inc is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CinRx Pharma

CinRx Pharma is a multi-asset biotech company focusing on advancing novel therapeutics that address large unmet medical needs.

Elicio

Elicio is committed to transforming the lives of patients and their families by re-engineering the body`s immune response to cancer. By combining expertise in materials science and immunology, Elicio is engineering potent vaccines and immuno-therapies for an array of aggressive cancers. The Elicio Amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, the “brain center” of the immune response, to significantly amplify and enhance the body`s own system of defenses, to defeat cancer and stop its recurrence. This substantially enhanced anti-tumor functionality and long-term protective memory could unlock the full potential of the human immune response to eliminate cancer. Elicio`s lead Amphiphile vaccines targeting pancreatic, colorectal, and head and neck cancer will begin initial patient studies in early 2020. Elicio was founded to expand and apply the ground-breaking Amphiphile technology invented and developed in the labs of Darrell Irvine Ph.D., Professor of Biological Engineering and Materials Sciences and Howard Hughes Investigator, at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. Preclinical studies have demonstrated that Elicio`s Amphiphile vaccines target and concentrate in the lymph nodes resulting in unprecedented tumor-specific immune responses and durable cures of aggressive tumor models in mice.